Levodopa in the treatment of Parkinson's disease: current controversies

Movement Disorders : Official Journal of the Movement Disorder Society
C Warren OlanowFabrizio Stocchi

Abstract

Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the "gold standard" against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor complications. Levodopa is toxic to cultured dopamine neurons, and this may be a problem in PD where there is evidence of oxidative stress in the nigra. However, there is little firm evidence to suggest that levodopa is toxic in vivo or in PD. Clinical trials have not clarified this situation. Levodopa is also associated with motor complications. Increasing evidence suggests that they are related, at least in part, to the short half-life of the drug (and its potential to induce pulsatile stimulation of dopamine receptors) rather than to specific properties of the molecule. Treatment strategies that provide more continuous stimulation of dopamine receptors provide reduced motor complications in MPTP monkeys and PD patients. These studies raise the possibility that more continuous and physiological delivery of levodopa might reduce the risk of motor complications. Clinical trials to test this hypothesis are underway. We review current evidence rela...Continue Reading

Associated Clinical Trials

References

Aug 1, 1992·Experimental Neurology·B Gomez-Mancilla, P J Bédard
Jan 1, 1992·Journal of Neurophysiology·T LjungbergW Schultz
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·M A MenaJ García de Yébenes
Jul 1, 1990·Trends in Neurosciences·M R DeLong
Mar 1, 1991·Journal of Neurochemistry·E SoficM B Youdim
Aug 1, 1990·Journal of Neuroscience Research·P P Michel, F Hefti
Aug 1, 1991·Journal of Neurochemistry·H H Kalir, C Mytilineou
Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Nov 1, 1990·Experimental Neurology·K Steece-CollierJ R Sladek
Oct 1, 1989·Trends in Neurosciences·R L AlbinJ B Penney
Sep 29, 1989·Biochemical and Biophysical Research Communications·Y MizunoY Kagawa
Nov 21, 1987·Lancet·D T DexterC D Marsden
Feb 1, 1989·Journal of Neurochemistry·P RiedererM B Youdim
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Apr 1, 1973·Journal of the American Geriatrics Society·A Barbeau
Oct 1, 1983·Mutation Research·P MoldéusB Lambert
Dec 13, 1982·Neuroscience Letters·T L PerryS Hansen
Jun 1, 1982·Neurology·A RechesJ Bhawan
Jun 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·C L LiG Cohen
Feb 1, 1995·Journal of Neurochemistry·A N BasmaH M Geller
Aug 1, 1994·Journal of Neurophysiology·H BergmanM R DeLong
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·S B BluntC D Marsden
Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·D T DexterC D Marsden

❮ Previous
Next ❯

Citations

Nov 26, 2010·Journal of Neurology·E HametnerW Poewe
Feb 9, 2008·Journal of Neural Transmission·David J BrooksHelena Nissinen
Mar 12, 2013·Journal of Neural Transmission·C Ossig, H Reichmann
Feb 7, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Giovanni AbbruzzeseDelia Colombo
Mar 30, 2006·Current Treatment Options in Neurology·Daniel Tarsy
Aug 18, 2010·Cell Biochemistry and Biophysics·Chuanqin FangChangyue Gao
Mar 22, 2013·CNS Drugs·Fabienne Sprenger, Werner Poewe
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Peter A LeWitt, Danette C Taylor
Sep 4, 2008·Journal of the International Neuropsychological Society : JINS·Berta Pascual-SedanoIgnasi Gich
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
Sep 9, 2005·The New England Journal of Medicine·John G Nutt, G Frederick Wooten
Dec 5, 2008·The New England Journal of Medicine·Peter A Lewitt
Oct 2, 2012·DNA and Cell Biology·Monica ColamartinoRenata Cozzi
Apr 3, 2008·Clinical Neuropharmacology·Mark Stacy, Andrew Galbreath
Jul 28, 2010·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Mar 16, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F GrandasUNKNOWN PRACTICOMT Study Group
Feb 3, 2006·International Journal of Clinical Practice·Jagdish C Sharma
Dec 27, 2007·Acta Pharmacologica Sinica·Serena RosnerAvi Orr-Urtreger
Jan 12, 2011·Doklady Biological Sciences : Proceedings of the Academy of Sciences of the USSR, Biological Sciences Sections·T G TolstikovaG A Tolstikov
Oct 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·A H V Schapira
Sep 17, 2009·AAPS PharmSciTech·Adnan AzeemSushama Talegaonkar
Jun 22, 2012·PloS One·Daniel T OmuraH Robert Horvitz
Apr 14, 2012·Clinical Interventions in Aging·Eva-Maria HametnerWerner Poewe
Sep 21, 2010·Clinical Interventions in Aging·Werner PoeweFrançois Vingerhoets
Sep 16, 2010·CNS Drugs·Angelo AntoniniGiovanni Abbruzzese
Oct 3, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Amaal AlDakheelAnthony E Lang
May 1, 2012·Journal of Movement Disorders·Eun Joo Chung, Sang Jin Kim
Mar 14, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Manon LebelMichel Cyr
Apr 2, 2009·Expert Opinion on Therapeutic Targets·Dieter D'hoedt, Daniel Bertrand
Nov 9, 2005·Expert Review of Neurotherapeutics·Mark F Lew
Jul 5, 2011·Expert Review of Neurotherapeutics·Santiago Perez-LloretOlivier Rascol
Dec 7, 2007·Expert Review of Neurotherapeutics·Mario Di NapoliDavid A Stewart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.